GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DarioHealth Corp (NAS:DRIO) » Definitions » Cash Flow from Financing

DarioHealth (DarioHealth) Cash Flow from Financing : $18.25 Mil (TTM As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is DarioHealth Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, DarioHealth paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, DarioHealth spent $0.00 Mil on financial activities for the three months ended in Dec. 2023.


DarioHealth Cash Flow from Financing Historical Data

The historical data trend for DarioHealth's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DarioHealth Cash Flow from Financing Chart

DarioHealth Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.25 27.55 65.77 61.94 18.25

DarioHealth Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 -1.39 19.44 0.20 -

DarioHealth Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

DarioHealth's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

DarioHealth's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DarioHealth  (NAS:DRIO) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

DarioHealth's issuance of stock for the three months ended in Dec. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

DarioHealth's repurchase of stock for the three months ended in Dec. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

DarioHealth's net issuance of debt for the three months ended in Dec. 2023 was $0.00 Mil. DarioHealth received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

DarioHealth's net issuance of preferred for the three months ended in Dec. 2023 was $0.00 Mil. DarioHealth paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

DarioHealth's cash flow for dividends for the three months ended in Dec. 2023 was $0.00 Mil. DarioHealth received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

DarioHealth's other financing for the three months ended in Dec. 2023 was $0.00 Mil. DarioHealth received $0.00 Mil on other financial activities.


DarioHealth Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of DarioHealth's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


DarioHealth (DarioHealth) Business Description

Traded in Other Exchanges
N/A
Address
18 W. 18th Street, New York, NY, USA, 10011
DarioHealth Corp is a digital health company. It offers user-centric a multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. DarioHealth serves customers globally.
Executives
Jon H. Kaplan director 1573 MALLORY LANE, SUITE 100, BRENTWOOD TN 37027
Erez Raphael director, officer: Chief Executive Officer 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Dennis M Mcgrath director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Dror Bacher officer: Chief Operating Officer 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK L3 3088900
Oded Cohen officer: GM MSK 8 HATOKHEN ST., CAESAREA INDUSTRIAL PARK L3 3088900
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Dennis Matheis director 8 HATOKHEN ST., CAESAREA L3 38900
Yoav Shaked director 8 HATOKHEN ST., CAESAREA L3 3088900
Yadin Shemmer director 8 HATOKHEN ST., CAESAREA L3 3088900
Richard Allan Anderson officer: President, GM of North America C/O DARIOHEALTH CORP., 18 W. 18TH ST, 5TH FLOOR, NEW YORK NY 10011
Yalon Farhi director C/O LABSTYLE INNOVATIONS CORP., 9 HALAMISH ST., CAESAREA INDUSTRIAL PARK, CAESAREA L3 3088900
Hila Karah director 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Zvi Ben-david officer: Chief Financial Officer 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Glen Moller director 8 HATOKHEN ST., CAESAREA L3 3088900
Olivier Roger Jarry officer: See Remarks 15 ROCKRIDGE RD, LARCHMONT NY 10538-3918